NuVasive ( NUVA) Gets Buy Rating

Raj Denhoy, analyst at Jefferies, has a Buy rating on NuVasive (NYSE: NUVA), a medical device company focused on products for the surgical treatment of the spine. The stock has been trading at $40.20 and Denhoy has a target price of $51.00 on the shares.

Growth of spinal medical products is slowing down but that should not deter NuVasive from achieving its growth objectives. The company is launching new products and there is still no real competition for its products like XLIF and NeuroVision. Gains in the share price will likely come if the company is able to capture increasing market share.